ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte ...
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not applicable; NGS, next-generation sequencing; PCR, polymerase chain reaction. Fig 1. Kaplan-Meier estimates of (A) ...
Araclon Biotech has provided early evidence that its Alzheimer’s disease vaccine is effective, linking the candidate to a 38% slowdown in disease progression compared to placebo in an exploratory ...
(RTTNews) - Immunic, Inc. (IMUX) Tuesday announced positive outcome from the interim futility analysis of its Phase 3 ENSURE program evaluating the company's lead asset, IMU-838 for the treatment of ...
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H AI-powered HER2 quantification continuous score (QCS) and tumor ...
Phase shift analysis remains a cornerstone of modern scattering theory, underpinning our understanding of how particles interact under various potential fields. By examining the phase differences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results